Alzheimer's disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer's disease and type 2 diabetes
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Globally, the incidence of type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) epidemics is increasing rapidly and has huge financial and emotional costs. The purpose of the current review article is to discuss the shared pathophysiological connections between AD and T2DM. Research findings are presented to underline the vital role that insulin plays in the brain’s neurotransmitters, homeostasis of energy, as well as memory capacity. The findings of this review indicate the existence of a mechanistic interplay between AD pathogenesis with T2DM and, especially, disrupted insulin signaling. AD and T2DM are interlinked with insulin resistance, neuroinflammation, oxidative stress, advanced glycosylation end products (AGEs), mitochondrial dysfunction and metabolic syndrome. Beta-amyloid, tau protein and amylin can accumulate in T2DM and AD brains. Given that the T2DM patients are not routinely evaluated in terms of their cognitive status, they are rarely treated for cognitive impairment. Similarly, AD patients are not routinely evaluated for high levels of insulin or for T2DM. Studies suggesting AD as a metabolic disease caused by insulin resistance in the brain also offer strong support for the hypothesis that AD is a type 3 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals and antioxidants in normal physiological functions and human disease
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.07.001 · Cited by 14,269 · cited 2×
“It leads to oxidation of proteins, lipids and DNA, causing damage to the mitochondria, as well as induction of genetic mutations in DNA/RNA [91]).”
BackgroundSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 1×
“It is estimated that the global diabetes mellitus (DM) prevalence will rise from 9.3% (463 million people) in 2019 to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045 [8].”
BackgroundInfluentialHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“The strongest genetic risk factor for AD is the e4 allele of apolipoprotein E (APOE4) relative to the e3 allele and the protective e2 allele [5,6].”
BackgroundType 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662 · cited 2×
“This dysfunction means that the secretion of insulin by the β-cells of the pancreatic islets (β-cell dysfunction) as well as the action of insulin on insulin-sensitive tissues such as the liver, adipose tissue and muscle do not function normally for the body (insulin resistance) [9].”
BackgroundProtein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629 · cited 1×
“AD and T2DM are both diseases that involve the formation of amyloid in various parts of the body [42,43].”
BackgroundAdvanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261 · cited 1×
“These products are protein molecules or peptides that are formed as a result of the Maillard reaction, meaning they become glycated as a result of their exposure to sugars [105].”
BackgroundTau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 1×
“In its normal state, tau protein is responsible for microtubule stability and regulating intracellular signaling [63–66].”
Background2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175 · cited 1×
“Insulin resistance affects the way insulin works in target tissues and cells, leading to the well-known phenomenon of hyperglycemia, a condition in which too much glucose circulates in the blood plasma and characterizes T2DM [9] T2DM has also been associated with an increased risk of dementia [10,11] and of AD by 45–9…”
Background
Cited by
Items 201–300 of 346
Nacre extract improves insulin resistance and cognitive functions in diabetic mice
Heng, Z., Yotsuya, Y., Omachi, T., & Hasegawa, Y. (2025) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/apjtb.apjtb_458_25 · Cited by 2
Ismail, A., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Faheem, S. A., & Batiha, G. E. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05493-1 · Cited by 2
Delivery systems for betalains: from stabilization strategies to precision nutrition applications
Luo, A., Zhao, Q., Zhang, X., Chen, J., Qin, L., Huang, R., Zheng, Q., & Zhong, S. (2025) · Food Research International · doi:10.1016/j.foodres.2025.118095 · Cited by 2
Silva, A., Silva, S., Rodrigues, B., Simões, G., Dinis, I., Freitas, M., Resende, R., Bicker, J., Fortuna, A. C., Silva, M. M., et al. (2025) · Oxidative Medicine and Cellular Longevity · doi:10.1155/omcl/7695056 · Cited by 2
“These overlapping mechanisms suggest a correlation between the two conditions, often referred to as brain-speci fi c T2D or type 3 diabetes [63].”
Glans, I., Mattsson, N., Strandberg, O. T., Stomrud, E., Ossenkoppele, R., van Westen, D., Spotorno, N., Hansson, O., & Palmqvist, S. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100448 · Cited by 3
“Dysregulated insulin signaling may further disrupt amyloid precursor protein (APP) metabolism, leading to enhanced A β production and aggregation [43].”
Yan, J., Tang, Z., Luo, Y., Liu, B., Huang, X., Wei, J., & Yue, F. (2026) · Advanced Science · doi:10.1002/advs.202516837 · Cited by 2
Mo, T., Zhuang, X., Zhao, W., Wang, B., Wang, Y., Ji, W., Dongguang, L., Zhang, G., Ru, Y., Xu, Y., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1704307 · Cited by 3
Li, S., Ding, W., Yu, Y., Chen, X., & Zhou, L. (2026) · Scientific Reports · doi:10.1038/s41598-026-38547-y · Cited by 4
“Simultaneously, pathways such as the AGE-RAGE signaling axis and serotonergic synapses (5-HT) suggest that glycation-induced damage and impaired neurotransmission may jointly contribute to cypermethrin-mediated neurotoxicity 30,31 .”
Isawi, I. H., Al‐Sawalha, N. A., Mahmoud, F., Al-Khawaldeh, I., & Alzoubi, K. H. (2026) · Journal of Experimental Pharmacology · doi:10.2147/jep.s561692 · Cited by 2
“6,7 These modifications resembled signs akin to expedited cerebral aging.”
Micro- and Nanoplastics and Human Health: Role of Food Nutrients Targeting Nfe2l2 Gene in Diabetes
Scuto, M. C., Lombardo, C., Musso, N., Bonacci, P. G., Lupo, G., Anfuso, C. D., & Salinaro, A. T. (2026) · Nutrients · doi:10.3390/nu18040600 · Cited by 2
“Noteworthy is the growing interest in the interrelationships between peripheral neuropathy and nephropathy in patients with T2DM [9,10].”
Association of type 2 diabetes treatment status with in vivo biomarkers of Alzheimer's disease
Akinci, M., Aziz, F., Guzman, D., Cheung, L., Kong, J. X., Silver, S. A., Eimicke, J. P., Teresi, J. A., Brickman, A. M., Lao, P. J., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71214 · Cited by 2
Kim, M., Byun, M. S., Yi, D., Ahn, H., Jung, G., Jung, J. H., Chang, Y. Y., Kim, K., Choi, H., Choi, J., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261418688 · Cited by 2
“4 Metformin, an insulin-sensitizing biguanide agent, stands as the most prescribed fi rst-line drug for glycemic control in T2DM.”
Progress on exercise therapy in type 2 diabetes mellitus with cognitive impairment
Xiang, Y., Zhao, Y., Huang, L., & Zhou, J. (2026) · Frontiers in Sports and Active Living · doi:10.3389/fspor.2026.1742195 · Cited by 3
“Central insulin resistance promotes hyperphosphorylation of tau protein, leading to neurofibrillary tangle formation, while competitively inhibiting insulin-degrading enzyme (IDE), thereby reducing β -amyloid (A β ) clearance and facilitating A β deposition (63).”
Xun, Y., & Zeng, W. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1777834 · Cited by 2
“Hyperglycemia promotes oxidative stress and the accumulation of advanced glycation end products (AGEs), contributing to neurovascular injury (Michailidis et al., 2022).”
Bukovics, M. P., Simon‐Szabó, L., Takács, I., & Németh, Z. (2026) · Cancers · doi:10.3390/cancers18142294 · Cited by 2
“Recent findings suggested that AD may represent a brain-specific form of diabetes (type 3 diabetes) [63].”
Braconi, L., Mattolini, L., Romanelli, M. N., Teodori, E., & Manetti, D. (2026) · Biomolecules · doi:10.3390/biom16071058 · Cited by 2
“Furthermore, increasing evidence suggests a role for PTP1B in neurodegenerative disorders, including Alzheimer’s disease, in which impaired insulin signaling in the brain has led to the concept of “type 3 diabetes” [17].”
Gentzel, M. (2024) · Journal of Bioethical Inquiry · doi:10.1007/s11673-024-10369-5 · Cited by 3
“The relationship between Alzheimer’s disease and metabolic dysfunction is so strong that many researchers now refer to it as “dia-betes of the brain” or “type 3 diabetes” (de la Monte and Wands 2008; Kandimalla et al. 2017; Nguyen et al. 2020; Michailidis et al. 2022).”
Diabetes Mellitus Impairs Blood‐Brain Barrier Integrality and Microglial Reactivity
Liu, S., Hao, J., Yu, T., Tuchin, V. V., Li, J., Li, D., & Zhu, D. Y. (2025) · Journal of Biophotonics · doi:10.1002/jbio.202400482 · Cited by 3
Glucose-lipid metabolic index reflects cognitive impairment of non-diabetic elderly individuals
Zeng, Y., Zhao, X., Sang, S., Yu, S., & Zhong, C. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251352548 · Cited by 3
Zhang, L., Wu, Y., Jin, Q., & Wang, C. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251359579 · Cited by 2
“17 This association has led to AD being referred to as “ type 3 diabetes ” .”
use of SGLT2 inhibitors in the treatment of cognitive disorders
Lato, M., Iberszer, K., Litwiniuk, M., Zaniuk, M., HURKAŁA, K., ANTONIK, D., Denys, B., Góra, K., Zimnicki, P., & Zdziennicki, W. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.25.01.003 · Cited by 2
The Role of Ion-Transporting Proteins in Human Disease
Marunaka, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031726 · Cited by 3
Robinson, L. S., Ashley, K. D., Ervin, T. B., Smith, T., & Lee, L. T. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105104 · Cited by 3
THE IMPACT OF METFORMIN USE ON RISK, PROGRESSION, AND SEVERITY OF DEMENTIA: A SYSTEMATIC REVIEW
Bekele, L. (2024) · doi:10.53555/jptcp.v31i7.6908 · Cited by 1
Should dietary restrictions be imposed on Alzheimer’s Disease patients affected by type 2 diabetes?
Ștefănescu, C., & Davidson, M. (2024) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2024.2392491 · Cited by 1
“It is therefore not surprising that this comorbidity has led to the creation of a new syndrome called Diabetes Type 3 (Michailidis et al. 2022).”
BackgroundDiabetes mellitus and neurodegenerative disorders
Amin, S. N., Albakri, K. A., Alabdallat, Y. J., & Elberry, D. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00009-9 · Cited by 1
Insulin resistance may hold the key to Alzheimer's disease
Winter, G. (2025) · British Journal of Nursing · doi:10.12968/bjon.2025.0056 · Cited by 1
Pathogenetic aspects of dementia in patients with type 2 diabetes mellitus
Romashevsky, B. V., Салухов, В. В., Maksim, O. V., & Duganova, A. V. (2025) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma630664 · Cited by 1
Cheng, M., Wei, Y.-D., Zheng, X., Gao, X., Sun, H., & Ge, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251351042 · Cited by 1
“54 Studies indicate that impaired brain insulin signaling drives metabolic and neurodegenerative disorders, establishing a mechanistic bridge between T2DM and AD.”
Markowicz-Piasecka, M., Laitinen, T., & Huttunen, K. M. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177886 · Cited by 1
Mechanisms of cognitive impairment in arterial hypertension
Kotlyarov, S. N. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v15.i7.106597 · Cited by 1
Huang, X., Xu, Z., Fu, F., Song, J., Zeng, J., Huang, S., & Yue, F. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110849 · Cited by 1
Jiang, C., Qi, J., Zou, H., López, O. L., Xie, X., & Xue, Y. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251365662 · Cited by 4
“21 Notably, metformin combined with DPP-4i or sulfonylur-eas was associated with a slower decline in MMSE scores compared to metformin combined with TZD.”
Ganic, D., Fajkić, A., & Lepara, O. (2025) · Cureus · doi:10.7759/cureus.93226 · Cited by 4
“The consequent metabolic dysfunction may further enhance oxidative stress, lipid peroxidation, mitochondrial damage, DNA injury, and neuronal vulnerability [20].”
Szabó, A., Farkas, S., Kádár, A., Török, B., Fazekas, C. L., Sipos, E., Bánrévi, K., Correia, P., Chaves, T., Kovács, T., et al. (2026) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2026.107839 · Cited by 1
Food and nutrition in the prevention of dementia–A mini-review
Lange, K. W., NAKAMURA, Y., & Lange, K. M. (2026) · Journal of Food Bioactives · doi:10.26599/jfb.2026.95033435 · Cited by 1
Fu, Y., Zhu, X., Liang, H., Fan, L., Shi, Q., Zhang, H., Sun, X., Wang, G., Deng, Y., & Li, W. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115784 · Cited by 1
Reticulocalbin‐2 in the Hippocampus Improves Cognitive Function of Diabetic Mice
Zhang, T., Tang, S., Cheng, J., Hu, B., Xie, L., Cheng, Y., Chen, X., & Xie, G. (2026) · Brain and Behavior · doi:10.1002/brb3.71336 · Cited by 1
“Both diabetes mellitus and Alzheimer’s disease represent multifactorial disorders with diverse biological pathways, prompting the proposal of terms like ‘diabetes type 3’ or ‘brain diabetes’ to comprehensively describe their potential shared pathogenic mechanisms (Michailidis et al. 2022 ).”
The neuro-metabolic epidemic and the CB1R paradox
Vaccaro, F., Malta, G., Rizzo, M., Plescia, F., & Lavanco, G. (2026) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2026.102631 · Cited by 1
Gao, X., & Wang, L. (2026) · Medicine · doi:10.1097/md.0000000000048685 · Cited by 1
Zhou, X., Wang, J., Yang, X., Huang, J., Fan, H., Wang, S., & Si, F. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.06.014 · Cited by 1
Unhealthy dietary patterns and Alzheimer’s disease: associations and underlying mechanistic pathways
Ramasinghe, C., & Xu, B. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2691237 · Cited by 2
“Added sugars, mainly from sweetened beverages and refined carbohydrates, also play an important role in the risk and progression of AD (González et al. 2022; Michailidis et al. 2022; Almeida et al. 2024).”
InfluentialMiR-7 in neurological disorders: beyond metabolic dysregulation
Puigdueta, C., Pardo, V., Torrecilla-Parra, M., Frutos, M. F.-D., López-Aceituno, J. L., Zamora, C., López-Manchedo, Y., Busto, R., & Ramírez, C. M. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1884638 · Cited by 1
“Particularly noteworthy is the growing body of experimental and epidemiological evidence linking diabetes to the development of AD, to the extent that AD associated with brain insulin resistance (IR) has been proposed as “Type 3 Diabetes” (Michailidis et al., 2022).”
Lei, Y., Liu, L., & Tang, Y. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103287 · Cited by 1
Alsharif, M., Shrebaty, O., Aloudah, M. A., Alqahtani, M., AlOubili, R. S., Ahmed, M. J., AlBani, B., & Bana, A. E. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1969490 · Cited by 1
Alzheimer Disease-Type 3 Diabetes: Traditional Review
Elkaan, B. T., Elmacıoğlu, F., & Ülker, M. T. (2023) · Turkiye Klinikleri Journal of Health Sciences · doi:10.5336/healthsci.2022-94043 · Cited by 1
Novel Strategy for Alzheimer’s Disease Treatment through Oral Vaccine Therapy with Amyloid Beta
Matsuzaka, Y., & Yashiro, R. (2023) · Biologics · doi:10.3390/biologics3010003 · Cited by 2
de Araújo, M. F. M., Barros, L. M., de Araújo, T. M., Teixeira, C. R. D. S., de Oliveira, R. A., Barros, E. A., Santos, F. S., Pascoal, L. M., Costa, A. C. P. D. J., & Neto, M. S. (2024) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2024.03.006 · Cited by 1
Association of dipeptidyl peptidase-4 with Alzheimer's disease: A new therapeutic prospect
Wang, X., Chen, L., Li, W., He, Z., & Hai-ying, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241304673 · Cited by 1
“44 Both T2DM and AD share the common pathological feature of amyloid accumulation, and even amylin accumulated in T2DM has a similar structural morphology with A β accumulated in AD.”
The Neuroprotective Effects of GLP-1 Analogues on Alzheimer's Disease – A Literature Review
Ulicka, W., Dudek, P., Łuczak, K., Chudzikowski, M., Pawlik, A., Pięta, J., Tabeau, A., Sitarek, H., Prus, J., & Prokopiuk, A. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.80.59398 · Cited by 1
Ren, X., Zhang, G., Zhou, B., Gu, W., Zhu, Q., & Liu, X. (2025) · Medical Physics · doi:10.1002/mp.70131 · Cited by 2
Li, Y., Xu, M., Tang, Y., Zhao, X., & Chen, M. (2026) · Current Diabetes Reviews · doi:10.2174/0115733998444053260211052025 · Cited by 1
Diabetes and Alzheimer's Disease
Bloomgarden, Z. T. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70103 · Cited by 1
“Aβ monomers play roles in neuronal synaptic activity, but Aβ has a tendency to autoaggregate, with reduction in IDE activity resulting in greater levels of Aβ, promoting plaque formation and contributing to AD pathology from Aβ accumulation, aggregation, and fibril formation [4].”
Deciphering PPAR-inducing pathway clarifying the link between Alzheimer’s Disease and diabetes
Shafie, N. S., Morsy Yasser, M., & Amer, M. (2023) · Annals of Pancreatic Disorders and Treatment · doi:10.17352/apdt.000010
Cai, L. (2023) · Nutrients · doi:10.3390/nu15112515
“Except for the common complications mentioned above, a new neuronal complication of diabetes has recently emerged and was recognized as having an Alzheimer’s disease (AD)-like pathology; therefore, some call AD type 3 diabetes (T3D) [8].”
BackgroundI Simpósio de Neurociências do Delta do Parnaíba
LINEUPI, L. A. P. D. N. (2024) · Jornal de Ciências da Saúde do Hospital Universitário da Universidade Federal do Piauí · doi:10.26694/jcshuufpi.v6isupl.2.5460
Diabetes Mellitus tipo 2 e a doença do Alzheimer na população idosa: uma revisão narrativa
Clementino, L. S., Matos, A. G. A. A. B., de Morais, R. B. A. R., Camurça, L. T., de Morais, P. C. L., de Lorena, G. C., de Morais, P. H. L., de Lima, W. W., Versa, L. C., & Balensiefer, D. V. (2024) · Contribuciones a las Ciencias Sociales · doi:10.55905/revconv.17n.4-148
Type 2 diabetes mellitus and Alzheimer's disease in the elderly population: A narrative review
Clementino, L. S., Matos, A. G. A. A. B., de Morais, R. B. A. R., Camurça, L. T., de Morais, P. C. L., de Lorena, G. C., de Morais, P. H. L., de Lima, W. W., Versa, L. C., Balensiefer, D. V., et al. (2024) · Seven Editora eBooks · doi:10.56238/sevened2024.010-036
Deciphering the impact of astrocytic insulin receptor depletion on Alzheimer's disease pathology
Ezkurdia, A. (2024) · Depósito Académico Digital Universidad de Navarra (University of Navarra) · doi:10.15581/10171/70017
Deterioro cognitivo en pacientes con diabetes: estudio de corte transversal
Trespalacios, R. H. D. J. F., Uribe, R. A. S., Hernández, E. F. M., & Suárez-Guerrero, J. L. (2024) · Acta neurológica colombiana · doi:10.22379/anc.v40i4.1864
Review of drugs effective in Alzheimer's disease
Dawood, S. H., & Zavadsky, S. P. (2024) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2412-13
Weng, M., Zhang, Y., Liang, C., & Yue, F. (2025) · Biophotonics and Immune Responses · doi:10.1117/12.3042127
“Type 2 diabetes mellitus (T2DM) is closely related to the development of AD, and Aβ, tau protein or islet amyloid can accumulate in T2DM and AD brains [6] .”
Song, J. H., Huang, X., Huang, S., & Yue, F. (2025) · Biophotonics and Immune Responses · doi:10.1117/12.3041550
“…a strong association between Type 2 Diabetes Mellitus (T2DM) and the development of AD, with both diseases reporting dysregulation of insulin receptors and insulin signalling pathway components, including protein kinase B, glycogen synthase kinase 3β and mammalian target of rapamycin 4,5,6 .”
Una nueva propuesta: diabetes tipo 3, una revisión narrativa
Pluma, V. H. C., Campos, V. Z., Weber, F. L. R., Jardines, R. C., ARAIZA, R. G., Gómez, A. C., Buenabad, D. G., & Domingo, M. A. (2025) · Acta Médica Grupo Ángeles · doi:10.35366/119354
Role of APOE in the Development of Diabetes Mellitus
Bastos‐Rodrigues, L., Moreira, S. H. C., & Gomes‐Fernandes, B. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_30-1
Identification of MicroRNA Drug Targets for Alzheimer's and Diabetes Mellitus Using Network Medicine
Castillo-Velázquez, R., Castañeda‐Delgado, J. E., García-Hernández, M. H., Rivas-Santiago, B. T., Ruiz-Hernández, S., Ortíz-Pérez, E., López-Alvarenga, J. C., Rivera, G., & Lara-Ramirez, E. E. (2025) · Current Alzheimer Research · doi:10.2174/0115672050393875250626065205
Ruíz-Ramos, M. (2025) · Casos y Revisiones de Salud · doi:10.22201/fesz.26831422e.2025.7.1s.1
Chronic inflammatory disorders and their redox control reaction
Duttaroy, A. K., & Jena, A. B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-43884-4.00011-8
Understanding the correlative relationship between obesity and Alzheimer disease
Foreman, R. M., & Rodriguez, M. (2025) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000355
Impact of oxidative stress on confluent diabetes and Alzheimer's disease
Ardhra, P. B., Thankachan, C., Devikrishna, P. R., Joshi, Y., & George, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-40559-4.00003-9
Insulin signaling in confluent diabetes and AD
Abraham, A., Gangadhara, V., & Baliga, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-40559-4.00008-8
Possible impact of co-occurrence of Alzheimer’s disease and diabetes and shared pathological traits
Adwani, G., & Kumar, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-40559-4.00007-6
ASSOCIATION OF DIABETES MELLITUS WITH REACTION TIME, COGNITIVE FUNCTION AND PHYSICAL FITNESS
Kierepka, U., Bieńkowska, K., Rosiewicz, M., Drzymała, J., Janda, A., Bartolik, S., Durowicz, M., Górnicka, I., Pastuszek, A., & Pastuszek, R. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4123
“High average glucose levels were related to an increase in risk of dementia among individuals without diabetes as well [59].”
InfluentialShared pathways in Alzheimer’s disease and type 2 diabetes mellitus
Karmakar, A., Dutta, S., & Mukhopadhyay, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00036-0 · Cited by 2
Direct consequences of diabetes on the nervous system: structural and molecular pathological changes
Mendes, O. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00003-7
Role of gut microbiome in diabetes and neurodegenerative diseases
Nabi, H., & Hossain, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00009-8
Wang, M., Xie, K., Zhao, S., Jia, N., Zong, Y., Gu, W., & Cai, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24186115
Wang, M., Xie, K., Zhao, S., Jia, N., Zong, Y., Gu, W., & Cai, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24186124
Wang, M., Xie, K., Zhao, S., Jia, N., Zong, Y., Gu, W., & Cai, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24186118
Jagait, A. (2023) · HARVEST (University of Saskatchewan)
Relationships Between Movement Behaviours And Dementia
Oye-Somefun, A. (2024) · YorkSpace (York University)
Alvarez-Gamez, K. (2025) · Repository of Digital Objects for Teaching Research and Culture (University of Valencia)
Nursing in primary care: the challenge of early detection of Alzheimer’s Disease
Ruiz, S. F. (2024) · UCrea (University of Cantabria)
Sun, Z., Han, J., Liu, H., Zeng, H., Li, R., Ji, W., Mao, D., Tian, X., & Shang, Q. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261418992
“43,44 In summary, our fNIRS data revealed no signi fi cant neu-rofunctional differences between T2DM-only and MCI-only groups during either tasks or resting-state.”
Le diabète de type 3 existe-t-il ? Les liens entre la maladie d’Alzheimer et le diabète de type 2
Delforge, S., Hans, C., & Lupant, A. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.007
A literature review on the relationship between diabetes and dementia
Chen, C., & Liao, D.-M. (2026) · 童綜合醫學雜誌 · doi:10.4103/etmj.etmj-d-25-00032
Karmakar, A., Roycowdhury, P., Sengupta, P., & Mukhopadhyay, D. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.02.007
Yoo, Y., & Joo, S. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062910 · Cited by 1
“This strong association has led to a compelling hypothesis that AD may, in part, result from metabolic dysfunction in the brain, supporting its proposed designation as T3D [11,47–51].”
Gong, H., Liu, J., Wang, Y., Lin, X., Wu, G., Ou, Y., Zhou, M., le Yang, Peng, J., Ye, X., et al. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103495
Skornyakova, T. S., Makhaeva, G. F., Zyryanova, E. Y., Musikhina, A. A., Рудакова, Е. В., Kovaleva, N. V., Boltneva, N. P., Konarev, P. V., Kiskin, M. A., Utepova, I. A., et al. (2026) · Russian Chemical Bulletin · doi:10.1007/s11172-026-4871-z · Cited by 3
Phung, P. T. K., Quan, L. M., Do, H.-H., Hung, T. M., Bon, N. V., Đoàn, M. D., Hong, T. T. X., Thu, N. H., Tuấn, N. Đ., & Đuc, N. K. (2026) · ChemistrySelect · doi:10.1002/slct.202505695
Balaan, C., Patwardhan, G. Y., Sachs, R. K., Kumasaka, H., Sadagopan, S., Aou, S., Lee, A. J., Nelson, L. T., Hew, B. E., Owens, J. B., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.14.717551
Kumar, I., Rani, D., & Pathania, K. (2026) · Current Trends in Pharmacy and Pharmaceutical Chemistry · doi:10.18231/j.ctppc.39626.1776405949
Metadata
- Authors
- Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V.
- Affiliations
- Laboratory of Psychology, School of Psychology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
- Aristotle University of Thessaloniki (GR)
- International Hellenic University (GR)
- Corresponding author
- Papaliagkas, Vasileios
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-02-28
- Volume
- 23
- Issue
- 5
- Pages
- 2687
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8910482
- OpenAlex
- W4214581316
- Cited by
- 330
- References
- 150
- Citations by year
- 2026: 79 · 2025: 110 · 2024: 71 · 2023: 61 · 2022: 9
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- Alzheimer's disease, type 2 diabetes, type 3 diabetes, insulin resistance, insulin signaling, neuroinflammation, oxidative stress, advanced glycation end products, mitochondrial dysfunction, metabolic syndrome, amyloid-beta, tau protein, amylin, cognitive impairment, brain energy homeostasis
- MeSH terms
- Alzheimer Disease, Brain, Diabetes Mellitus, Type 2, Humans, Insulin, Insulin Resistance, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
